.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,703,781

« Back to Dashboard

Claims for Patent: 8,703,781

Title:Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Abstract: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-tr- ioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2- -fluorophen-}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
Inventor(s): Dumble; Melissa (Collegeville, PA), Kumar; Rakesh (Collegeville, PA), Laquerre; Sylvie (Collegeville, PA), Lebowitz; Peter (Collegeville, PA)
Assignee: GlaxoSmithKline LLC (Philadelphia, PA)
Application Number:13/499,779
Patent Claims: 1. A combination comprising: (i) a compound of formula (I) ##STR00026## or a pharmaceutically acceptable salt or solvate thereof; and (ii) a compound of formula (II) ##STR00027## or a pharmaceutically acceptable salt thereof.

2. A combination according to claim 1 wherein compound (I) is in the form of the dimethylsulfoxide solvate and the compound (II) is in the form of the methanesulfonate salt.

3. A combination kit comprising a combination according to claim 1 together with a pharmaceutically acceptable carrier or carriers.

4. A combination according to claim 1 for use in therapy.

5. A combination according to claim 1 for use in treating cancer.

6. A pharmaceutical composition comprising a combination according to claim 1 together with a pharmaceutically acceptable diluent or carrier.

7. A method of treating melanoma in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I) ##STR00028## or a pharmaceutically acceptable salt or solvate thereof; and (ii) a compound of formula (II) ##STR00029## or a pharmaceutically acceptable salt thereof.

8. The method of claim 7, wherein compound (I) is in the form of the dimethylsulfoxide solvate.

9. The method of claim 7, wherein the melanoma is metastatic melanoma.

10. The method of claim 7, wherein compound (II) is in the form of the methanesulfonate salt.

11. The method of claim 7, wherein the melanoma is BRAF V600E mutant melanoma.

12. A method of treating metastatic melanoma having a BRAT V600E mutation in a human in need thereof which comprises the administration of a therapeutically effective amount of (i) a compound of formula (I) ##STR00030## or a pharmaceutically acceptable salt car solvate thereof; and (ii) a compound of formula (II) ##STR00031## or a pharmaceutically acceptable salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc